Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause
Primary Purpose
Metabolic Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
exercise
Hormone treatment
Sponsored by
About this trial
This is an interventional prevention trial for Metabolic Syndrome
Eligibility Criteria
Inclusion Criteria:
- women
- going through oophorectomy to prevent hereditary cancer
- premenopausal
Exclusion Criteria:
- infection during the last month
- chronic disease
- smoking
- alcohol > 14 servings/week
- hysterectomized
- premature menopause
- BMI > 30
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Placebo Comparator
No Intervention
Arm Label
training + HT
training - HT
-training + HT
- training - HT
Arm Description
training + HT
training - HT
-training + HT
- training - HT
Outcomes
Primary Outcome Measures
insulin sensitivity
Measured by a hyperinsulinemic euglycemic clamp as AUC for glucose infusion rate
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02525276
Brief Title
Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause
Official Title
Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Unknown status
Study Start Date
August 2015 (undefined)
Primary Completion Date
August 2018 (Anticipated)
Study Completion Date
August 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main objective of this study is to investigate the role of female sex hormones in relation to insulin resistance in a controlled human experimental model of menopause and to explore whether exercise and/or hormone treatment (HT) can compensate for loss of endogenous sex hormone production by maintaining insulin sensitivity and metabolic activity at a level equivalent to what is seen in premenopausal women.
Loss of ovarian function is associated with an increased incidence of metabolic disease including metabolic syndrome, type 2 diabetes and cardiovascular disease. This increased disease incidence seems to be related to changes in body composition including decreased skeletal muscle mass and increased visceral fat mass as well as decreased whole body fat oxidation and energy expenditure. Regular physical activity decreases general mortality among other things by increasing fat free mass and insulin sensitivity and hereby prevents metabolic syndrome and cardiovascular disease - conditions seen with an increased incidence after menopause and could therefore be a possible treatment.
In the present study the Investigators will assess the role of sex hormones in a model of menopause where healthy women are undergoing planned bilateral oophorectomy due to risk of hereditary ovary cancer. The use of this model makes it possible to control the time point for loss of ovarian function and hereby investigate the timeframe and possible contributing factors in a strictly controlled model. 48 premenopausal women will be included in the study. The study is conducted in women who have already been offered surgical oophorectomy. The first 2 months the study will be an observational cohort study. Hereafter the patients will be allocated to one of four groups (n=12) in a randomized controlled trial, addressing the effects of 6 months of exercise with or without HT. Type of surgery has been decided before inclusion based on medical indications. The women will be offered HT according to national guidelines, but the choice is up to them. Randomization applies only to the training intervention.
Firstly the Investigators aim at investigating the role of endogenous female sex hormones and HT in relation to insulin resistance, whole body fat oxidation and -energy expenditure, changes in visceral fat mass and fat free mass after oophorectomy. Secondly, the Investigators wish to study the molecular mechanisms behind the oophorectomy-induced insulin resistance with a focus on insulin signaling in skeletal muscle and fat tissue. Lastly, the investigators aim to explore whether exercise and/or HT can compensate for loss of endogenous female sex hormone production by maintaining IS and metabolic activity, hereby preventing future incidents of metabolic disease in relation to menopause.
All in all, this project will contribute with new knowledge concerning the question of how endogenous female sex hormones affect insulin sensitivity and metabolic functioning and how exercise may be used as a disease preventive modality for middle-aged women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
training + HT
Arm Type
Experimental
Arm Description
training + HT
Arm Title
training - HT
Arm Type
Experimental
Arm Description
training - HT
Arm Title
-training + HT
Arm Type
Placebo Comparator
Arm Description
-training + HT
Arm Title
- training - HT
Arm Type
No Intervention
Arm Description
- training - HT
Intervention Type
Behavioral
Intervention Name(s)
exercise
Intervention Description
The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
Intervention Type
Drug
Intervention Name(s)
Hormone treatment
Intervention Description
Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.
Including:
Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat
Primary Outcome Measure Information:
Title
insulin sensitivity
Description
Measured by a hyperinsulinemic euglycemic clamp as AUC for glucose infusion rate
Time Frame
1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
women
going through oophorectomy to prevent hereditary cancer
premenopausal
Exclusion Criteria:
infection during the last month
chronic disease
smoking
alcohol > 14 servings/week
hysterectomized
premature menopause
BMI > 30
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Julie Abildgaard, MD
Phone
+4535457190
Email
julieabild@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julie Abildgaard, MD
Organizational Affiliation
Centre of Inflammation and Metabolism
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause
We'll reach out to this number within 24 hrs